Skip to content

Effectiveness and Safety of Topical JAK Inhibitor for Non-Segmental Vitiligo: A Multicenter Real-World Study

Effectiveness and Safety of Topical JAK Inhibitor for Non-Segmental Vitiligo: A Multicenter Real-World Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500106366
Enrollment
Unknown
Registered
2025-07-23
Start date
2025-08-06
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-segmental Vitiligo

Interventions

Ruxolitinib Phosphate Cream Treatment group:NA

Sponsors

Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
12 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >=12 years at the time of signing informed consent, regardless of gender; 2. Clinically diagnosed with non-segmental vitiligo, meeting: Facial BSA >=0.3% ,F-VASI >=0.3, total body depigmentation area <=10% BSA; 3. Agreement to practice highly effective contraception during the study and for 6 months after the last dose, with no pregnancy plans; 4. Voluntary provision of written informed consent and commitment to regular follow-up visits.

Exclusion criteria

Exclusion criteria: 1. Presence of other hypopigmentary disorders that may interfere with efficacy assessment (e.g., pityriasis alba, leprosy, post-inflammatory hypopigmentation, idiopathic guttate hypomelanosis, nevus depigmentosus, chemical leukoderma, tinea versicolor); 2. a) Hypersensitivity to the investigational drug or its excipients; b) Concurrent participation in other clinical trials; 3. Deemed ineligible by the investigator based on clinical judgment.

Design outcomes

Primary

MeasureTime frame
Proportion of Patients Achieving >=75% Improvement in Facial Vitiligo Area Scoring Index (F-VASI);safety;

Secondary

MeasureTime frame
Changes from baseline in F-BSA (Face Body Surface Area), T-BSA (Total Body Surface Area), F-VASI (Face Vitiligo Area Scoring Index), and T-VASI (Total Vitiligo Area Scoring Index) scores;1.The proportion of patients achieving F-VASI(Face Vitiligo Area Scoring Index) 50/75/90 ; 2.The proportion of patients achieving T-VASI(Total Vitiligo Area Scoring Index) 50/75/90 .;Proportion of patients achieving a Vitiligo Noticeability Scale (VNS) score of 4 ("less noticeable") or 5 ("no longer noticeable") ,along with the percentage distribution w;Changes from baseline in DLQI (Dermatology Life Quality Index) and CDLQI (Children's Dermatology Life Quality Index) scores;

Countries

China

Contacts

Public ContactQing Guo

Sun Yat-sen Memorial Hospital, Sun Yat-sen University

guoqingzsy@163.com+86 20 8133 2235

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026